Health
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
PRINCETON, N.J., March 20, 2026--Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/620c8faf3d67bdb1a14e6892360d0911"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KcZ8BHcYjYvxzPS1TjTOJw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMg--/https://media.zenfs.com/en/business-wire.com/620c8faf3d67bdb1a14e6892360d0911","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/eYgegjWZSvp3Tl056.4Uzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA-/https://media.zenfs.com/en/business-wire.com/620c8faf3d67bdb1a14e6892360d0911","width":1200,"height":165}},"lazy":false},{"type":"text","content":"In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin Lymphoma (cHL)","length":287,"tagName":"p","attribs":{}},{"type":"text","content":"With approval in the EU, Opdivo in combination with brentuximab vedotin is now the first immunotherapy combination approved to treat certain pediatric and adult patients with relapsed or refractory cHL","length":201,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., March 20, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S. and the European Union (EU). The U.S. Food and Drug Administration (FDA) granted approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL.1 In the EU, the European Commission (EC) approved Opdivo in combination with brentuximab vedotin for the treatment of children 5 years of age and older, adolescents, and adults up to 30 years of age with relapsed or refractory cHL after one prior line of therapy.2","length":763,"tagName":"p"},{"type":"text","content":""These approvals represent a defining moment for people living with classical Hodgkin Lymphoma," said Monica Shaw, MD, Senior Vice President of Oncology Commercialization. "In the U.S., ...